Score Breakdown
Offering Ability
46
Cash Runway
65
Float Risk
57
Warrant Exposure
40
Convertible Debt
85
Dilution Forecast
⛈️
Warning
High probability of dilution event
model est. 53%
🔄 Reverse Split
model est. 65%
• 50-day avg $0.88 below $1 exchange minimum
• 10 months cash with weak price
🔁 Convertible Conversion
model 60%
• Major convertible overhang: 156% potential dilution
• Convertible risk score very high (85/100)
💰 Capital Raise
model 15%
• Under 12 months cash (10mo)
Market Data
Market Cap$3.21M
Shares Outstanding20.56M
Float9.31M
Cash$17.64M
Debt$38.09M
Short InterestN/A
Institutional Holdings
QoQ: ↓ 99.9% shares (2026Q1 vs prior)
2 institutional holders · 960 shares
#1
MORGAN STANLEY
732 shares
#2
SIMPLEX TRADING, LLC
228 shares
Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.
Short Interest
No current FINRA short-interest record is available for this ticker.
Recent SEC Activity
xbrl
XBRL CONVERTIBLE
2025-12-31
Full SEC filing analysis available with free account →
Recent News
No recent news
Factual CASI Dilution Snapshot
CASI Pharmaceuticals, Inc. (CASI) has a DilutionScore of 58/100, rated High dilution risk. Score date: August 28, 2026.
- Recent SEC activity tracked for CASI: xbrl on 2025-12-31.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Related Stocks — HIGH Risk
Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles: